A5019688174- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Angiogenesis and VEGF in Cancer
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Chronic Kidney Disease and Diabetes
- Pharmaceutical Practices and Patient Outcomes
- Adrenal and Paraganglionic Tumors
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Chemotherapy-induced cardiotoxicity and mitigation
- Neutropenia and Cancer Infections
- Ferroptosis and cancer prognosis
- Venous Thromboembolism Diagnosis and Management
Dana-Farber Cancer Institute
2014-2024
Harvard University
2013-2017
John Wiley & Sons (United States)
2016
University of Washington Medical Center
2016
Cancer Research Center
2016
Dana-Farber Brigham Cancer Center
2016
Brigham and Women's Hospital
2016
Fred Hutch Cancer Center
2016
VEGF signaling pathway inhibitor (anti-VEGF) therapy is associated with hypertension, but little known about predisposing clinical characteristics. This study describes the real-world association between baseline characteristics, blood pressure (BP) response, and survival in patients prescribed anti-VEGF therapies.Clinical data from Partners HealthCare Massachusetts was obtained adults treated therapies (2002-2013). Treatment-induced hypertensive response defined as worsening of preexisting...
Abstract Purpose: The renin-angiotensin system may play a role in carcinogenesis. purpose of this study was to evaluate the impact angiotensin inhibitors (ASI) on outcomes metastatic renal cell carcinoma (mRCC) patients treated targeted therapy era. Experimental Design: We conducted pooled analysis mRCC phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors Kaplan–Meier method. Results: A total 4,736 included, whom 1,487...
Background Immune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees severity. While clinical experience ICI retreatment following clinically significant irAEs is growing, the safety and efficacy are not yet well characterized. Methods This multicenter retrospective study identified patients metastatic renal cell carcinoma treated who had >1 week therapy interruption for irAEs. Patients were classified into discontinuation cohorts...
<h3>Background</h3> Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are still not well established. Programmed Death Ligand-1 (PD-L1) expression ACC and its association with clinico-pathological features survival outcomes unknown. <h3>Methods</h3> Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 28 patients ACC. PD-L1 was evaluated by immunohistochemistry (IHC) both cell membrane infiltrating mononuclear cells (TIMC). positivity on defined as...
BACKGROUND Vascular endothelial growth factor (VEGF)–targeted therapies are standard treatment for metastatic renal cell carcinoma (mRCC); however, toxicities can lead to drug discontinuation, which affect patient outcomes. This study was aimed at identifying risk factors toxicity and constructing the first model predict toxicity‐related discontinuation (TrTD) in mRCC patients treated with VEGF‐targeted therapies. METHODS The baseline characteristics, outcomes, data were collected 936...
Background There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) advanced urological cancers as they are generally excluded from clinical trials due to risk exacerbations. Methods This multicenter retrospective cohort analysis renal cell cancer (RCC) urothelial (UC) pre-existing AD treated CPI catalogued incidence exacerbations, new immune-related adverse events (irAEs) outcomes. Competing models estimated...
Background Accurate estimation of kidney function is essential for patient selection and drug dosing in patients with cancer. eGFR equations are necessary decision making monitoring. Our aim was to identify which these equations—estimated creatinine clearance (eCrCl) by Cockcroft-Gault (CG), Modification Diet Renal Disease (eGFR MDRD ), CKD Epidemiology Collaboration CKD-EPI ) or the recently proposed Janowitz-Williams equation J-W )—would be most suitable GFR among cancer receiving...
353 Background: Everolimus and temsirolimus are mammalian target of rapamycin (mTOR) inhibitors used in a variety malignancies including renal cell carcinoma (RCC). These targeted agents have been associated with unique set adverse events infections. We performed an up-to-date meta-analysis published clinical trials to further characterize the risk infections cancer patients treated mTOR inhibitors. Methods: Pubmed oncology conference proceedings were searched for studies from January 1966...
653 Background: The pivotal clinical trials of CPI generally excluded pts with AD given concern for serious exacerbations. There is limited data on the safety and efficacy in this population. Methods: We conducted a retrospective single center analysis RCC UC treated CPI. Pts were grouped by presence or absence AD. catalogued incidence new irAEs (CTCAEv4), exacerbations, objective response rate (ORR, RECIST 1.1), overall survival (OS, Kaplan Meier). Competing risk models estimated cumulative...